Authors
Latest:
Palliative Care Begins at Diagnosis, Not at End of Life"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes most medical professionals."
Latest:
Oncology Drug Crash Course: Lenvatinib (Lenvima) for Advanced Endometrial CancerLenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.
Latest:
The Road Ahead: Future Directions in Metastatic Melanoma TreatmentPanelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising advances in melanoma treatment and the role of telehealth and community outreach in expanding access and improving outcomes.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Antibiotic Overuse During COVID-19 Pandemic Exacerbates Need for Firmer Prescription Policies, Expert SaysThe reality of the COVID-19 pandemic will force lawmakers to firmly act on behalf of antibiotic policies, according to an expert with Pew Charitable Trusts.
Latest:
Your Workforce Should Reflect Your CommunityDiversity, equity, and inclusion must be a centerpiece of nursing recruitment and retention.
Latest:
Closing Reflection: A Journey of Understanding and ResiliencePanelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Latest:
Johanna Garibaldi On Strengthening Cancer Prevention Tactics With Mobile Screening ClinicsJohanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.
Latest:
Managing Infection Risk With Bispecific Antibodies in MyelomaNurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.
Latest:
Evaluating Options for Second-Line HR+, HER2- Breast Cancer TreatmentKatherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.
Latest:
Jessica MacIntyre on Improving LLS Referrals For Patients With Hematologic MalignanciesJessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.
Latest:
Long-Term Care in ALK+ NSCLCPanelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.
Latest:
Supporting Patients Through Treatment for Advanced NSCLCPanelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain fog and weight gain while maintaining disease control, emphasizing the importance of multidisciplinary team support, including palliative care from diagnosis.
Latest:
Unmet Needs and Future Perspectives on the treatment of R/R MMExperts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.
Latest:
Verina on Tackling Neurological Toxicities From CAR T-Cell TherapyDaniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Latest:
Nivolumab Combo for RCC Necessitates AE Monitoring, AwarenessAccording to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.
Latest:
Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid TumorsExperts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.
Latest:
Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast CancerUpdates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.
Latest:
Rx Road Map: Durvalumab for Non-Small Cell Lung CancerRead Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.
Latest:
Life After CAR T Therapy: Insights for Patients and Referring OncologistsThis video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.
Latest:
Supporting the Novice Oncology NP: The Benefits of PreceptorshipStructured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
Immediate Interventions to Support The Newly BereavedWhen engaging with a family member of a patient who has died, nurses should consider using immediate interventions aimed at supporting the loved ones who are in shock and in pain following their loss.
Latest:
Jennifer Cargile on Managing Cancer-Related Cognitive ImpairmentJennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.
Latest:
IHC May Sub as NGS for Early TP53-Mutant MDS/AML DetectionAn observational study found IHC may serve as a biomarker for early detection of TP53‐mutant MDS or AML and prediction of TP53 allelic state.
Latest:
Liquid Biopsies Are More Feasible, Appropriate for ESR1+ Breast CancerUsing liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.
Latest:
Oncology Therapy at the End of Life: Have We Missed the Mark?"Over the last decade, the landscape of systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," - Kerin Adelson, MD.
Latest:
Oncology Drug Crash Course: Elacestrant (Orserdu)Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Latest:
Charina Toste Discusses the Educational Obstacles Patients With MPNs FaceAccording to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.
